Aim To define recommendations that permit safe management of antineoplastic medication, minimise medication errors and improve the safety of cancer patients undergoing treatment. Methods By reviewing the literature and consulting the websites of various health organisations and agencies, an expert committee from the Spanish Society of Hospital Pharmacy and the Spanish Society of Medical Oncology defined a set of safe practices covering all stages of providing cancer therapy to patients. The Spanish Society of Oncology Nursing revised and endorsed the final list. Results In total, 68 recommendations arranged in five sections were defined. They include issues concerning the training of health professionals, the technological resources needed, treatment planning, informing the patient and his/her family, the processes of prescribing, preparing, dispensing and administering cancer therapy (orally, parenterally or intrathecally), assessing patient adherence and treatment toxicity. Conclusions It is essential for healthcare establishments to implement specific measures designed to prevent medication errors, in order to ensure the safety of cancer patients treated with antineoplastic medication.
Introduction
The rising incidence and prevalence of cancer, and the rapid development of new treatment strategies, have resulted in greater diversity and complexity of cancer therapies in recent years. Because of improved survival and quality-oflife outcomes in many cancers, together with greater use of the oral route and better tolerability of many new drugs, increasing numbers of patients are receiving cancer therapy in oncology departments. This situation poses new challenges for achieving safe management of cancer drugs by the health professionals involved.
For decades, cancer therapy (particularly chemotherapy) has been the prime example of high-risk medication. The risk of fatality or serious complications entailed in chemotherapy [1] , including cases with major social repercussions such as intrathecal delivery errors [2] , has led the scientific community to introduce hitherto unheardof multidisciplinary practices for validating and doublechecking treatment, in order to improve cancer patient safety [3, 4] . With the aim of preventing various types of errors and risks of adverse effects in patients, a wide range of recommendations have been published in recent years [5, 6] . They include standardisation of treatment orders [7] , safe labelling [8] [9] [10] , checklists [11] or, more recently, computer order entry systems integrated with electronic health records and machine-readable coding during administration [12] [13] [14] [15] . All these measures have contributed greatly to improving safety [16] , but do not entirely guarantee it [17] . Those recommendations were subsequently incorporated into national and international standards and guidelines [5, [18] [19] [20] [21] [22] [23] by the American Society of Clinical Oncology (ASCO) and the Oncology Nursing Society (ONS) [24] [25] [26] , the American Society of Health-System Pharmacists (ASHP) [27] and the Institute for Safe Medication Practices (ISMP), among others [28, 29] . Complying with certain standards is a mandatory requirement in current cancer care quality systems [30] .
However, in the context of growing patient safety demands and rapid introduction of new treatments, establishing safe basic procedures may not be enough. In particular, the advent of oral drugs for non-hospital use has not been accompanied by the same safety requirements now in place for intravenous chemotherapy in the oncology hospital setting [31] . That has generated new risks and challenges in cancer patient care, such as monitoring adherence and educating patients about their treatment [32, 33] , resulting in new recommendations specifically for oral therapy [34, 35] , now included in the latest versions of international publications [24, 25, 27] .
In Spain, no consensus document is yet available in which a full set of multidisciplinary measures is defined for the safe treatment of cancer patients with antineoplastic drugs. Some advisable practices are contained in other reports, such as the recent Strategic Plan for Pharmaceutical Care in Oncology/Haematology Patients by the Spanish Group for the Development of Oncology Pharmacy (GEDEFO) [36] or the document on oncology day hospitals produced by the Spanish Society of Medical Oncology (SEOM) [37, 38] .
The aim of this work has been to define a set of multidisciplinary safety recommendations for managing antineoplastic medications, to help prevent medication errors and improve the safety of cancer patients in Spain.
Methods
These consensus recommendations are based on a review of the available evidence about safe practices in cancer therapy, and the professional opinions of the Spanish Society of Medical Oncology (SEOM), the Spanish Society of Hospital Pharmacy (SEFH) and Spanish Society of Oncology Nursing (SEEO) experts.
Literature review
To identify safe practices regarding antineoplastic drug management, a structured literature search was performed in the PubMed database for publications on cancer therapy recommendations and safety and quality standards. The search was confined to articles published in English or Spanish between 1 May 2007 and 31 April 2017. The search syntax employed included the combination of MeSH descriptors and keywords or text words shown in Table 1 . This search identified 85 publications, from which 23 in total were finally selected by reading the abstracts [1, 2, 4, 6, 7, 9, 11-13, 16-19, 24, 25, 27, 28, 30-33, 35, 39] .
The literature search was supplemented by a manual search for secondary references cited in the articles initially selected [3, 5, 8, 15, 34] . A manual search for documents about standards or recommendations for safe practices with cytostatics was also performed on the websites of the following health organisations and agencies: [37, 38] .
Initial selection of safe practices by an expert committee
For the production of this document, SEOM and SEFH set up a committee of experts in cancer therapy and drug safety, composed of four specialists from each society.
The first stage involved the experts analysing the publications selected during the literature search, in order to identify and compile safe practices covering all stages of cancer therapy provision. The expected benefits were taken into account, as was the feasibility of incorporation into Spanish healthcare practice. This stage identified 74 safe practices, which were discussed and screened at a meeting attended in person by the expert committee members. Several rounds of revision then took place between the committee members, working remotely. At the end of this process, 68 practices were selected in total.
Revision of selected practices by independent professionals, and production of the consensus statement
The expert committee drafted a set of recommendations for the safe management of cancer medication, containing the 68 selected practices. This draft was e-mailed to various health professionals belonging to SEFH and SEOM, who had been chosen in advance for their knowledge of this field. They were asked for comments and suggestions about the practices included, in terms of content and wording. They were also given the opportunity to suggest the inclusion of new practices.
All the comments and suggested amendments to the contents and form of the document, sent by the health professionals consulted, were analysed and discussed by the expert committee until an agreed draft list of safe practices was achieved.
This draft list of safe practices was then submitted for review and endorsement to the SEEO, which suggested additional comments and amendments to clarify some practices. These amendments were discussed by the expert committee and were included in the final document. Table 2 contains the full list of safe practices for the management of cancer therapy agreed by this expert committee. This list includes 68 practices divided into five sections, following a scheme like the one used in the ASCO/ ONS chemotherapy administration safety standards [24] . "Introduction" contains 17 general measures intended for healthcare establishments, about the training of health professionals involved in cancer patient treatment, the human and technological resources needed, the standard operating procedures that should exist, and procedures for continuity of care and risk management. "Methods" supplements the above with nine practices related to cancer therapy planning, informed consent, and informing the patient and his/her family or carers about medication. Section 3 of Table 2 contains 33 practices addressing the stages of prescribing, preparing, dispensing and administering oral and parenteral cancer therapy, including specific measures for intrathecally delivered medication. This section is supplemented by "Discussion", which contains five practices on treatment monitoring, including the assessment of patient adherence and cancer treatment toxicity. Lastly, the four practices in Sect. 5 briefly highlight the importance of ensuring the safety of health professionals who prepare and administer antineoplastic medication. It was decided that in-depth consideration of this issue was beyond the scope of this document, because it did not form part of the initial aim of these recommendations.
Results

Discussion
Medication safety management is a critical aspect of cancer patient care. Because antineoplastic drugs have a narrow therapeutic range, medication errors that can arise for various reasons during the course of treatment carry a high risk of causing patients serious adverse effects or compromising the clinical benefit of therapy. Safe practices to minimise them and prevent unnecessary harm to patients must, therefore, be implemented. Aware of this need, SEFH and SEOM have worked closely together to produce a multidisciplinary document that brings together a set of fundamental practices to ensure the safety of cancer patient care. Starting from a literature review, an expert committee produced a set of recommendations tailored to Spain. These were revised by a group of independent professionals from both societies and endorsed by the SEEO.
The recommendations are intended for healthcare establishments and professionals who provide parenteral and oral cancer therapy, either with commercially available medications or with clinical research products. The
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recommendations address all stages involved in the process of providing cancer drug treatment, from prescribing to patient monitoring. Additionally, they cover other measures considered essential for improving cancer patient safety, some of which entail profound change in an organisation's culture. Examples include continuing professional development and assessment of competence, standardisation of all working procedures and healthcare protocols, and setting The continuing professional development requirements demanded of staff, which should be updated at least once a year 1.1.3. The criteria for accreditation by authorised independent organisations, and how this accreditation is documented 1.1.4. The criteria for assessing the competence of professionals 1.1.5. A full training programme that ensures compliance with the established requirements for initial and continuing training for all categories of staff who prescribe, dispense, prepare and administer cancer therapies 1.2. The hospital has sufficient staff to ensure that individuals assigned to each healthcare process are suited to the volume of work, so that established safe practices are is followed and high-risk behaviour encouraged by high pressure on care staff is avoided 1.3. At least one specialist in medical oncology and one oncology nurse trained in basic life support are at the hospital and are available immediately when the antineoplastic therapy is administered 1.4. The hospital has an information and communication technology-based integrated information system for the management of cancer patients (inpatients, outpatients and external patients). It is integrated into the single medical record and the hospital's information systems, so that full information about the cancer patients and their medication is available to all health professionals who provide them with care, including emergency care 1.5. The hospital has in place standard operating procedures designed to prevent errors, containing clear definitions of the processes for medical prescribing, pharmaceutical reviewing, preparing, dispensing, administering and monitoring antineoplastic therapy, and staff responsibilities in each process 1.6. The hospital has up-to-date, evidence-based treatment protocols, clearly and unambiguously written, and accessible to all health professionals involved in cancer patient care. Those protocols specify at least the following aspects of each treatment regimen: . Pain assessment 1.9. At each visit, the patient's treatment is reviewed and updated if required by the oncologist and validated by the pharmacist 1.10. Oral antineoplastic therapy is subject to the same documentation, prescribing, checking and dispensing procedures as parenteral therapy 1.11. Antineoplastic treatments given in clinical trials should follow the same safe practices described in this document as for commercially available treatment, in order to prevent medication errors 1.12. At the first consultation, before each treatment cycle begins, a structured procedure is used to obtain a full list of medication being taken by the patient, including prescription and non-prescription drugs, vitamins, herbal medicines and substance abuse, and that list is compared and reconciled with drugs prescribed during the consultation and upon any subsequent transition of care. At the following consultations, a procedure will be used to learn of subsequent changes in treatment, and they will be reviewed by the pharmacist 1.13. The hospital has in place a standard procedure for reconciling treatment at discharge, which ensures appropriate education of patients or carers and good communication with professionals who care for the patient, to ensure suitable treatment monitoring 1.14. The hospital has a full-time emergency department for dealing with treatment-related adverse reactions and emergencies in cancer patients. If required, an oncologist can be consulted, and there is the option of transferring the patient to a site with specialist oncology services 1.15. The hospital has rules in place for recording and reporting adverse drug reactions 1.16. The hospital has an interdisciplinary patient safety or risk management committee, which has set up a reporting system enabling health professionals to report adverse events, potential events and medication incidents that occur at the site. The committee analyses these incidents in order to introduce measures designed to prevent their recurrence. It also reviews external errors and published information about new safe practices and develops and implements effective practices for improving the safety of cancer therapy 1.17. The hospital has a general or specific quality management system for oncology procedures, which is accredited or certified by an external body 2. Treatment planning, patient consent and information 2.1. The hospital has a standard procedure for obtaining informed consent from patients and documenting it before they receive cancer therapy 2. If appropriate, the instructions should state how drugs should be taken as regards food intake, and whether certain food types can affect the efficacy or toxicity of the medication 3.6.13. Prescriber's ID, including his/her signature or corresponding electronic ID 3.7. All prescription orders for cancer therapies, including oral medication, must be validated by a hospital pharmacist specifically dedicated to cancer therapy 3.7.1. Validation is mandatory as an independent preliminary step in treatment preparation 3.7.2. In order to validate the treatment order, the pharmacist checks the patient's previous treatment (paying attention to cumulative maximum doses), and verify all drugs and administration routes, scheduling, if all doses are correct according to patient weight, BSA and renal and liver function, potential interactions, the patient's allergies, dose adjustments related to previous adverse effects, compliance with site protocols, and whether patient blood counts and other laboratory results allow the treatment to be administered 3.7.3. If any discrepancies are found in the validation process, they must be resolved with the prescribing physician before the preparation process continues 3.8. The hospital has a system for ensuring that preparation is safe and traceable, covering all stages from the prescribing to the administration of antineoplastic drugs 3.8.1. Antineoplastic therapies must be prepared under the control and supervision of the hospital pharmacy department 3.8.2. When antineoplastic therapies administered on-site are prepared off-site, the external site must satisfy all the general requirements for quality, safety and traceability 3.9. It must be ensured that antineoplastic therapies are prepared by specifically trained staff 3.9.1. Antineoplastic therapy must be prepared by health professionals trained to prepare such treatments, and under the direction of a specifically dedicated hospital pharmacist 3.9.2. Health professionals (nurses, technicians) involved in preparing antineoplastics must know the rules of cytotoxic drug management and receive specific training before they start work and regularly thereafter 3.10. The material resources available must allow antineoplastic medication to be prepared under conditions of safety for both patient and healthcare staff, according to legislation and good manufacturing practice 3.10.1. Cancer drugs should be prepared in clean rooms, under negative pressure and using aseptic technique 3.10.2. Specific Class II Type B2 biosafety cabinets are used for preparing cytostatics, and personal protective equipment is worn, in accordance with current regulations 3.10.3. Only authorised staff is allowed in the preparation area 3.10.4. Each site should assess whether it is cost-effective to use robots for preparing cytostatics. These devices improve the accuracy of preparation and provide additional elements of safety 3.11. There should be a safety policy for selecting and storing antineoplastic drugs, aimed at preventing errors with drugs that have similar names or packaging, and to avoid the coexistence at the hospital of presentations of different strengths. If the usual presentations are changed, staff must be informed, and the computer program updated 3.12. The pharmacy department has standard guidelines or protocols specifying the composition, reconstitution, dilution, stability, labelling, etc. of each drug used in cancer therapies at the site 3.13. Antineoplastic therapy is prepared in the cabinet for one patient at a time, and each drug is prepared individually 3.14. Antineoplastic therapy is prepared in such a way that no further preparation is required by the health professional responsible for administering the treatment. Priming of intravenous tubing and syringes is performed inside the safety cabinet 3.15. A standardised labelling method is available for ensuring easy identification of patient, medication, route and dose. Labels are printed (not handwritten). Mixtures are labelled as soon as they are prepared. The label is checked against the physician order and the worksheet. Labelling for injections includes: 3.15.1. Patient's full name 17. In the case of cancer medication pertaining to a clinical trial, as well as the above-mentioned points, the guidance for the trial protocol is followed. The clinical trial protocol and the time of preparation are stated on the labelling 3.18. The components of intravenous mixtures of cancer drugs are verified using bar codes or a similar system. Additionally, a gravimetric method is used to verify correct preparation of the mixture. If this is not possible, the filled syringes and vials are independently doublechecked by staff other than the person who prepared them, before they are added to the final solution. The check performed is recorded in writing 3.19. After the prepared mixture has been verified, the antineoplastic drug is inserted into a plastic bag with a leak-proof closure. Transparent bags facilitate identification by nursing staff, with no need for unpacking. Bags are transported in an easily washed, rigid container, identified with the cytotoxic hazard symbol, containing an absorbent plastic pad at the bottom 3.20. Until they are transported, prepared mixtures are stored, in accordance with the storage conditions, in a properly identified, purposedesigned area, bearing in mind the stability data for the mixture 3.21. Prepared mixtures are transported by properly trained healthcare staff. The use of mechanical transport systems such as pneumatic tubes is not recommended 3.22. Antineoplastic therapy is administered by a qualified member of nursing staff 3.23. Before antineoplastic therapy is first administered, an expert nurse must check for the presence of risk factors for extravasation. If several factors are present, prior insertion of a central line should be evaluated 3.24. Before each administration of antineoplastic therapy, patient ID is verified by an expert nurse in the presence of the patient, using at least two identifiers: full name, and a second unambiguous identifier (medical record number, date of birth, or verification by national ID card when administration takes place outside the hospital) 3.25. Before the start of each administration cycle, an expert nurse confirms the treatment with the patient: drug name, infusion time, route of administration, and infusion-related symptoms that must be reported, stipulating which symptoms must be reported urgently by the patient 3.26. Before each administration of cancer therapy, the following are verified and documented by an expert nurse: 3.26. up risk management systems. All of these are crucial for improving safety. These recommendations also incorporate the minimum technological and human resources that need to be available at healthcare centres in order to reduce variability of care provided, ensure fairness, and assure the safety of cancer therapy. Today, cancer is regarded as a chronic disease, and oral antineoplastic therapies are increasingly used. Together, these two facts have required patient care strategies to change direction, towards a cooperative multidisciplinary model, in which it is particularly important to inform and talk to the patients and/or carers who will have to be actively involved in treatment. One whole section of recommendations is, therefore, devoted to this. The document contains other fundamental practices in these patients, such as monitoring adherence and reconciling treatments during transitions of care.
The practices listed in this consensus statement are not intended as safety standards for healthcare establishments, because the scientific societies that produced them do not provide certification. Nevertheless, these specific measures aimed at preventing medication errors should obviously be adapted and implemented by healthcare establishments, in order to improve the safety of the care they provide. This document is also intended to assist health professionals, The hospital has a procedure for evaluating, at each visit by the patient, his/her treatment adherence as well as the toxicity associated and its treatment 4.4. The hospital has a procedure for evaluating and documenting treatment-related adverse reactions and dose adjustments required, and for reporting them before subsequent administration 4.5. For drugs associated with cumulative toxicity, the doses administered are monitored 5. Staff safety 5.1. Health professionals are adequately trained in safety procedures and updated in hazardous drugs handling, and wear personal protective equipment suitable for preparing, dispensing and administering cancer drugs, and for handling the patient's body fluids 5.2. The hospital employs standard operating procedures for preparation and administration, which ensure the safety of people handling cancer drugs, including the use of closed system transfer devices (CSTD) to reduce the risk of vapours and aerosols being released 5.3. The hospital has a protocol to manage accidental exposures and a spill kit is available, with appropriate instructions for use, for those cases, which are registered 5.4. The hospital has policies and procedures regarding cytotoxic waste management, in accordance with current legislation 1 3 who can use the recommendations as a benchmark for their healthcare practice.
Lastly, it should be noted that SEFH, SEOM and SEEO intend to promote the development of initiatives to encourage the introduction of these recommendations, and to update them periodically, when new practices are developed that affect the safety of cancer therapy. The aim is for patients receiving antineoplastic therapy in Spain to do so with maximum assurances of quality and safety.
